The U.S. Food and Drug Administration (USFDA) on Friday approved Merilog as biosimilar to Novolog (insulin aspart) for the ...

Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients ...

The U.S. Food and Drug Administration approved Merilog as biosimilar to Novolog for the improvement of glycemic control in adults and pediatric ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

This human insulin analogue that comes in disposable pens prefilled with 1, 1.5, or 3 mL, dosed in 10-unit increments1 binds reversibly to albumin, which extends its half-life to around 7 days. Steady ...

This strategic investment reflects our commitment to responsible investing, addressing critical global healthcare challenges like the growing need for insulin analogues. Moreover, it strengthens ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Today, Plantsulin blends this century-old discovery with modern scientific validation to offer a fast, convenient “whole-body reboot” for maintaining optimal glucose levels. Unlike restrictive diets ...

A thorough examination of modern drugs that target particular receptors and metabolic pathways for glucose and fat metabolism is presented. Recent research has revealed innovative targets and ...